title: Vascular effects of sustained-release fibroblast growth factors.
abstract: Since the half-life of most angiogenic growth factors is several hours or less, sustained-release delivery would be optimal for their future clinical use. Two fibroblast growth factors, basic fibroblast growth factor (bFGF) and endothelial cell growth factor (ECGF), were delivered in two sustained-released modalities (poloxamer 407 and a gelatin sponge [Gelfoam]) to attempt to increase soft tissue vascularity. In vitro bioactivity of ECGF-poloxamer formulations was also tested on endothelial cell cultures. Among vascular-compromised skin flaps in rabbits, ECGF-poloxamer (N = 26), bFGF-poloxamer (N = 5), ECGF-poloxamer (N = 9, irradiated), and bFGF-Gelfoam flaps (N = 22) did not demonstrate significant differences in viability and vascularity compared to controls (p > .05). Irradiation had a detrimental effect on both flap vascularity and viability (p = .02). Future efforts for sustained delivery of angiogenic proteins are critical in order to make them clinically useful in wound healing.
authors.affiliation: Department of Otolaryngology-Head and Neck Surgery, University of Minnesota School of Medicine, Minneapolis 55455, USA.
authors.forename: D B
authors.initials: DB
authors.lastname: Hom
authors.forename: K
authors.initials: K
authors.lastname: Medhi
authors.forename: G
authors.initials: G
authors.lastname: Assefa
authors.forename: S K
authors.initials: SK
authors.lastname: Juhn
authors.forename: T P
authors.initials: TP
authors.lastname: Johnston
mesh_terms: D000818:Animals; D002478:Cells, Cultured; D003692:Delayed-Action Preparations; D016228:Endothelial Growth Factors / Q000008:administration & dosage* / Q000627:therapeutic use; D016222:Fibroblast Growth Factor 2 / Q000008:administration & dosage* / Q000627:therapeutic use; D005781:Gelatin Sponge, Absorbable; D006801:Humans; D066298:In Vitro Techniques; D018919:Neovascularization, Physiologic; D014677:Pharmaceutical Vehicles; D011060:Poloxalene; D011817:Rabbits; D011833:Radiation Injuries, Experimental / Q000628:therapy; D017695:Soft Tissue Injuries / Q000628:therapy*; D013524:Surgical Flaps / Q000502:physiology; D014945:Wound Healing / Q000187:drug effects / Q000502:physiology / Q000528:radiation effects
chemical_list: D003692:Delayed-Action Preparations; D016228:Endothelial Growth Factors; D014677:Pharmaceutical Vehicles; D016222:Fibroblast Growth Factor 2; D011060:Poloxalene